Abstract P057: The Association Between Diabetes and Risk of Abdominal Aortic Aneurysm: A Meta-Analysis

Circulation ◽  
2018 ◽  
Vol 137 (suppl_1) ◽  
Author(s):  
Lu Yao ◽  
Aaron Folsom ◽  
Alvaro Alonso ◽  
James Pankow ◽  
Weihua Guan ◽  
...  

Objectives: Data regarding the relationship between diabetes and abdominal aortic aneurysm (AAA) are inconsistent across studies: some studies showed an inverse relationship while others did not show an association. We conducted a meta-analysis to examine the association between diabetes and AAA based on published data from case-control and cohort studies. Methods: We searched literature in English from online databases including MEDLINE (1966-), EMBASE and Web of Science as of July 2017, plus a manual examination of references in selected articles. The eligibility criteria included (1) a case-control or cohort study conducted in adults; (2) diabetes is the exposure variable and AAA risk is the outcome variable; and (3) association estimates (hazard ratios, odds ratios or relative risks) and measurement of variance (P value, confidence interval, or standard error) were available. The literature review and data abstraction were conducted in duplicate by independent investigators. A DerSimonian and Laird random effects model was used to pool association estimates and their 95% confidence intervals from studies using STATA 13. The Cochran’s Q test was used to assess the presence of heterogeneity and the I-square index to quantify the extent of heterogeneity. Results: We included in the meta-analyses a total of 10 cohorts with 10,771 AAAs in 2,625,318 participants and 4 case-control studies with 1,065 AAAs and 11,009 controls that met the pre-determined eligibility criteria. The samples were predominantly white (88%). Study-specific relative risk and pooled relative risk as well as heterogeneity test results were shown in Figure. Diabetes was inversely associated with AAA risk (pooled relative risk: 0.55; 95%CI: 0.49 - 0.61, Figure) . Results were overall consistent by sex, study design and setting (hospital- vs community-based). Conclusions: The findings suggest that diabetes is strongly and inversely associated with the risk of AAA. Future studies are warranted to investigate the potential mechanisms.

2020 ◽  
Vol 199 (2) ◽  
pp. 513-526
Author(s):  
Tingting Chen ◽  
Hongliang Zhang ◽  
Yang Zhang ◽  
Mengqi Yang ◽  
Juntao Wu ◽  
...  

Author(s):  
James Phie ◽  
Shivshankar Thanigaimani ◽  
Jonathan Golledge

Objective: There are no current effective abdominal aortic aneurysm (AAA) drug therapies. An important limitation of most preclinical studies is that they test the effect of drugs on AAA formation rather than AAA progression. The aim of this study was to systematically review AAA mouse model studies that have tested the effect of interventions in limiting the progression of preestablished AAA. Approach and Results: The literature search identified 35 studies meeting eligibility, and 30 (n=935 mice) contributed to the meta-analyses. AAAs were induced with angiotensin II (n=745 mice), calcium chloride (n=91 mice), or elastase (n=99 mice). Anti-inflammatory drugs (standardized mean difference [SMD], 1.62 [95% CI, 0.93–2.30]), protease inhibitors (SMD, 1.23 [95% CI, 0.52–1.95]), stem cells (SMD, 1.64 [95% CI, 1.05–2.24]), antiplatelet or anticoagulant drugs (SMD, 0.93 [95% CI, 0.63–1.22]), and renin-angiotensin system inhibitors (SMD, 1.45 [95% CI, 0.58–2.33]) reduced AAA diameter. Interventions initiated soon after model induction commenced were more likely to reduce AAA diameter (R 2 , 16%; P =0.007). Funnel plots suggested possible publication bias. Most studies did not report blinding or sample size calculations, and the risk of bias was considered medium or high in 20 (57%) of the 35 studies. Conclusions: There is low-quality evidence that a range of drugs are effective in limiting AAA progression when administered early after AAA induction in mouse models. Some of these drugs, such as antiplatelet and renin-angiotensin system inhibitors, have been reported to be ineffective in clinical trials.


PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e85831 ◽  
Author(s):  
Hui Cao ◽  
Xinhua Hu ◽  
Qiang Zhang ◽  
Jun Li ◽  
Junpeng Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document